- Eli Lilly dominates first-half biotech acquisitions, with no sign of slowing downRiding on its trillion-dollar heft and successes in treating obesity, Eli Lilly has now become a force in one area where it hasn’t historically been the main player: M&A. The Indianapolis-bas…Endpoints · 18d ago↗ source
- Catalent to divest UK site; Rottendorf, Evonik announce manufacturing buildsPlus, news about RoslinCT, Novo Nordisk and more. 🇬🇧 Catalent to sell UK site to Codis: The CDMO is set to take Catalent’s oral solid dose factory in Nottingham, with ...Endpoints · 18d ago↗ source
- GSK walks away from Alector pact as immuno-neurology bet fizzlesAfter two high-profile trial failures over the past year, GSK is breaking off a deal that features $700 million upfront that it signed with Alector for neurodegenerative disease treatments. GSK’s…